Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.

In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.

Join global experts Prof. Salvatore Oliva and Dr. Dhandapani Ashok for an educational symposium at ESPGHAN, as they discuss the burden and impact of underlying type 2 inflammation in eosinophilic esophagitis (EoE), and the importance of early diagnosis and management in pediatric patients.

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses the significant risk of developing other atopic diseases among infants with early-onset atopic dermatitis.
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim provides an overview of itch in type 2 inflammatory skin diseases and explains how the shared and unique mechanisms that drive inflammation and itch mediate each disease in distinct ways.
Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria (CSU). They offer practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.

This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.